XSHG
603567
Market cap738mUSD
Oct 09, Last price
5.40CNY
1D
2.66%
1Q
12.97%
Jan 2017
-72.67%
IPO
-71.11%
Name
HeiLongJiang ZBD Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
6.36
EPS
—
Div yield, %
2.85%
Shrs. gr., 5y
2.05%
Rev. gr., 5y
-25.18%
Revenues
798m
-70.49%
Net income
-1.37b
L
CFO
322m
+96.03%
Dividend
Aug 20, 20250.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Heilongjiang ZBD Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the entire lifecycle of Traditional Chinese Medicine (TCM), from research and development to manufacturing and sales, exclusively within China. Its extensive product portfolio addresses a wide spectrum of health concerns, including conditions related to cardiovascular and cerebrovascular health, respiratory ailments, orthopedic issues, oncology, digestive disorders, anti-infective treatments, neuropsychiatric conditions, and genitourinary problems, among others. Established in 1996, the company maintains its headquarters in Hulin, China.
Key people
Tonghua Fang
Chairman of the Board · since 2019
Lei Wang
Chief Financial Officer · since 2023
Jiujiang Yan
General Manager, Director · since 2022
Tianzhu Li
Deputy General Manager · since 2022
Xiuzhen Li
Deputy General Manager · since 2023
Zhongfang Zhang
Secretary of the Board · since 2023
Jing Huang
Staff Elected Director · since 2025
Yunqi Zhang
Director · since 2019
Ruichao Lin
Independent Director · since 2021
Zhiqun Wang
Independent Director · since 2024
Headquarters & legal address
市黑龙江省鸡西市虎林市虎林镇红星街72号
哈尔滨市, HL 100000
CN
哈尔滨市, HL 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||